Autism Research and Treatment / 2012 / Article / Tab 2

Research Article

Safety and Observations in a Pilot Study of Lenalidomide for Treatment in Autism

Table 2

Parameter estimates for each subject who underwent pharmacokinetic testing at 1, 2, 4, and 8 hours.

ID 𝐶 m a x (ng/mL) 𝑡 m a x (h)AUCT (ng/mL)

123.351112.35
252.062167.36
354.411179.19
457.741219.72
5153.571327.54
660.642281.29
719.46159.39

Mean60.181.29192.41
SD44.430.4992.93

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.